Share This Page
Suppliers and packagers for VIDAZA
✉ Email this page to a colleague
VIDAZA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | VIDAZA | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 050794 | NDA | Celgene Corporation | 59572-102-01 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (59572-102-01) | 2004-07-05 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: VIDAZA
Introduction
VIDAZA (azacitidine) is an FDA-approved chemotherapeutic agent primarily used in the treatment of myelodysplastic syndromes (MDS) and certain other hematologic malignancies. As a nucleoside metabolic inhibitor, VIDAZA plays a vital role in the management of bone marrow disorders, making its supply chain critically important for healthcare providers globally.
Given the increasing demand and the complex manufacturing process, identifying reliable suppliers for VIDAZA is imperative for pharmaceutical companies, healthcare institutions, and governments. This article provides an in-depth analysis of the key suppliers, manufacturing landscape, and market dynamics surrounding VIDAZA.
Overview of VIDAZA and Its Market Significance
VIDAZA is produced by Celgene Corporation (a Bristol-Myers Squibb company following acquisition), with active pharmaceutical ingredients (APIs) and finished products supplied worldwide. Its therapeutic significance stems from its unique mode of action—incorporating into DNA to inhibit methyltransferases, thereby reactivating tumor suppressor genes.
The global demand for VIDAZA has risen steadily due to its efficacy benefits, leading to heightened competition among suppliers and a diversification of manufacturing sources. The drug's complexity underscores challenges related to production scalability, quality control, and regulatory compliance.
Major Suppliers of VIDAZA
1. Celgene/Bristol-Myers Squibb
As the original patent holder and producer, Celgene (now part of Bristol-Myers Squibb) remains a principal supplier of VIDAZA. The company controls the core manufacturing facilities for both the API and finished formulations. Their robust global distribution network ensures wide availability, especially in North America and Europe.
Manufacturing Facilities
Celgene's manufacturing plants are located in strategic regions, including the United States and Europe. These facilities are GMP-certified and licensed to produce high-quality azacitidine.
Supply Chain Reliability
Bristol-Myers Squibb prioritizes supply stability to meet high global demand, investing in manufacturing process improvements and capacity expansion.
2. Contract Manufacturing Organizations (CMOs)
Given the drug’s complex synthesis, several CMOs have been engaged by Bristol-Myers Squibb and other integrators to supplement production capacity. These CMOs specialize in sterile injectable manufacturing and nucleoside synthesis.
Key CMOs include:
- Fujifilm Diosynth Biotechnologies: Known for its expertise in biologics and complex APIs, Fujifilm has been involved in manufacturing several nucleoside analogs, including azacitidine.
- Almac Group: With capabilities in small molecule synthesis and sterile manufacture, Almac supports API production and finished dosage forms.
- Patheon (Thermo Fisher Scientific): Provides contract manufacturing services for sterile injectables, including azacitidine formulations.
This network of CMOs enhances supply flexibility and capacity, critical for responding to global demand spikes.
3. Emerging and Regional Suppliers
While the primary supply is controlled by Bristol-Myers Squibb, certain regional manufacturers have entered the scene, often in response to patent expirations and increased biosimilar activity in the oncology segment.
Potential regional sources include:
- Manufacturers in India and China, such as Hetero Labs and Cipla. These companies have capability in generic nucleoside analogs but currently lack approvals for VIDAZA-specific formulations in major markets.
Note: These regional companies primarily produce generic azacitidine, subject to regulatory approval, and may not currently supply branded VIDAZA.
Market Dynamics and Supply Chain Considerations
Regulatory Environment
Regulatory agencies like the FDA and EMA impose stringent GMP standards for the production of VIDAZA. Manufacturers must ensure compliance with evolving regulatory expectations, impacting supplier qualification and approval timelines.
Manufacturing Challenges
The synthesis of azacitidine involves complex chemical processes with sensitive handling requirements, strict quality controls, and contamination prevention protocols. These challenges limit the number of high-quality, GMP-certified suppliers.
Patent and Market Exclusivity
While patent protections for VIDAZA have expired in some jurisdictions, branded suppliers retain market dominance through regulatory exclusivities and supply chain expertise. Entry of generic producers is consequently limited and often proceeds after patent expiry or via biosimilar pathways.
Supply Chain Risks
Disruptions can arise from geopolitical issues, raw material shortages, or manufacturing delays. The COVID-19 pandemic highlighted vulnerabilities, prompting suppliers to diversify manufacturing sites and establish buffer inventories.
Price and Procurement Trends
Supplier consolidation and limited production licenses contribute to high and stable pricing. Procurement decisions focus on securing reliable supply sources, with centralized tendering occurring in countries with national health systems.
Future Outlook and Potential Suppliers
As patents expire and biosimilars enter the market, more suppliers are poised to emerge, especially from Asia. However, establishing GMP-certified, high-quality production lines specific for injectable chemotherapeutics like VIDAZA remains a lengthy and capital-intensive process.
Advancements in manufacturing technology, such as continuous flow chemistry, could lower barriers, enabling new entrants. Strategic partnerships or licensing agreements might also facilitate market expansion through regional manufacturing.
Concluding Remarks
The supply landscape for VIDAZA is primarily dominated by Bristol-Myers Squibb (Celgene) with support from specialized CMOs. While current supply chains are stable, complexities associated with API synthesis, regulatory requirements, and market dynamics underscore the importance of continuous monitoring.
Healthcare providers and procurement entities must stay informed of potential supply disruptions and emerging manufacturers, particularly as generics and biosimilars progress through regulatory pathways. Enhanced transparency and diversified sourcing will be critical to maintaining uninterrupted access to this vital therapeutic.
Key Takeaways
- Bristol-Myers Squibb (via Celgene) remains the primary global supplier, leveraging extensive manufacturing infrastructure and established distribution channels.
- Contract manufacturing organizations play a crucial role in augmenting capacity and ensuring supply flexibility.
- Regulatory compliance and complex synthesis processes limit the number of high-quality, GMP-certified suppliers.
- Emerging regional manufacturers, especially in Asia, are exploring generic azacitidine production but face hurdles in product approval and quality standards.
- Supply chain resilience depends on diversification, technological innovation, and strategic partnerships to address evolving market demands and mitigate risks.
FAQs
1. Who are the primary global suppliers of VIDAZA?
The main supplier is Bristol-Myers Squibb (formerly Celgene), supported by a network of CMOs such as Fujifilm Diosynth and Almac, which supplement manufacturing capacity.
2. Are generic azacitidine equivalents available?
While several companies produce generic azacitidine, regulatory approvals for these products as equivalent to VIDAZA vary globally. Currently, branded VIDAZA remains dominant in major markets.
3. How does manufacturing complexity affect VIDAZA supply?
The synthesis of azacitidine involves sensitive, multi-step processes with strict quality controls, limiting the number of capable, GMP-certified manufacturers and impacting supply stability.
4. What risks threaten VIDAZA supply chain stability?
Risks include manufacturing disruptions, raw material shortages, geopolitical issues, regulatory delays, and unforeseen events like pandemics.
5. What is the outlook for new suppliers?
With patent expirations and technological advancements, new regional manufacturers and biosimilar entrants may develop, but high-entry barriers mean supply dominance may remain with established players for the foreseeable future.
Sources
[1] Bristol-Myers Squibb. "Vidaza (azacitidine) prescribing information."
[2] U.S. Food and Drug Administration (FDA). "VIDAZA Approval History."
[3] Industry reports on nucleoside analog production.
[4] Market analysis on oncology drug supply chains.
[5] Regulatory guidance documents on GMP standards for sterile injectables.
More… ↓
